Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-endotrophin monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- The University of Texas System
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
The anti-endotrophin monoclonal antibody is a preclinical-stage biologic research compound developed by the University of Texas System (specifically UT Southwestern Medical Center, with inventor Philipp E. Scherer) that targets endotrophin (ETP), a pro-fibrotic and pro-inflammatory cleavage product of the C5 domain of the alpha3 chain of collagen VI (COL6A3). By neutralizing endotrophin, the antibody aims to reverse epithelial-mesenchymal transition (EMT), reduce tissue fibrosis, and inhibit tumor angiogenesis and metastasis. It has been investigated in preclinical models for its potential to overcome treatment resistance in breast cancer (particularly when combined with platinum-based chemotherapies like cisplatin or endocrine therapies), as well as for treating chronic fibroinflammatory conditions such as renal fibrosis, diabetic nephropathy, fatty liver disease, and adipose tissue fibrosis, while also improving insulin sensitivity.
- Other names
- anti-endotrophin antibodyanti-endotrophin mAbendotrophin-neutralizing antibody
02
Targets
ETP (Endotrophin)
Beyond the preview
Go deeper on anti-endotrophin monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-endotrophin monoclonal antibody.